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Possible Neurologic Effects of Aspartame,
a Widely Used Food Additive
by Timothy J. Maher* and Richard J. Wurtmant
The artificial sweetener aspartame (L-aspartyl-L-phenylalanyl-methyl ester), is consumed, primarily in
beverages, by a very large number ofAmericans, causing significant elevations in plasma and, probably,
brain phenylalanine levels. Anecdotal reports suggest that some people suffer neurologic or behavioral
reactions in association with aspartame consumption. Since phenylalanine can be neurotoxic and can
affect the synthesis of inhibitory monoamine neurotransmitters, the phenylalanine in aspartame could
conceiveably mediate neurologic effects. If mice are given aspartame in doses that elevate plasma phen-
ylalanine levels more than those oftyrosine (which probably occurs after any aspartame dose in humans),
the frequency of seizures following the administration of an epileptogenic drug, pentylenetetrazole, is
enhanced. This effect is simulated by equimolar phenylalanine and blocked by concurrent administration
ofvaline, which blocks phenylalanine's entry into the brain. Aspartame also potentiates the induction of
seizures by inhaled fluorothyl or by electroconvulsive shock. Perhaps regulations concerning the sale of
food additives should be modified to require the reporting ofadverse reactions and the continuing conduct
of mandated safety research.
Introduction: Food Additives as
Neuroactive Environmental
Constituents
Forthe very great majority ofAmericans, i.e., those
who elect to eat processed foods, food additives are a
ubiquitous constituent oftheenvironment, and onewith
potentially important health effects. The laws govern-
ing the sale of these compounds require that their ad-
dition to foods fulfill a specific purpose, such as improv-
ing flavor, retarding spoilage, or enhancing nutritional
quality, and that such use be risk-free. Implicit in this
latter requirement is the expectation that the food ad-
ditive not be found to affect physiological processes
other than the nutritional or sensory ones underlying
its use: Compounds that do affect physiological systems
are classified as drugs by the Food and Drug Admin-
istration (FDA), and are subject to considerably more
demanding regulatory procedures than food constitu-
ents. Moreover, because food additives must be shown
to be physiologically inert in order to win initial FDA
approval, once they have obtained this approval they
are exempted from the requirement, imposed on all
drugs, that their safety be continuously monitored:
Companies that manufacture and use approved food ad-
ditives are not obligated to monitor adverse reactions
associated with consumption of their product, nor to
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submit to the FDA reports of such adverse reactions;
they also are not required to carry out further govern-
ment-mandated researchprogramstoaffirmtheirprod-
uct's safety.
However, the consumption of a number of food ad-
ditives can causephysiologicaleffects whichinclude, for
some, modificationofthechemicalcompositionandfunc-
tional activities ofthe nervous system (1,2). These ef-
fects may generate health risks for some people. More-
over, in the case of one such compound, the artificial
sweetener aspartame (L-aspartyl-L-phenylalanyl-
methyl ester), these neural effects were largely unex-
plored priortothe compound's additionto the food sup-
ply, and were not a factor in calculating the quantities
that individuals can safely consume (the ADI, or ac-
ceptable daily intake, currently set for aspartame at 50
mg/kg) (3). The effects of aspartame, and of certain
other food additives, like caffeine, on the nervous sys-
tem are sometimes not ofsuch anature asto allowtheir
detection by the standard neurotoxicological tests used
to assess the safety offood additives, inasmuch asthese
effects need not be associated with cell death, nor with
other visible manifestations of neuronal damage.
Rather, they involve more subtle biochemical changes,
as well as functional consequences that are demonstra-
ble only in specially treated animals (4) (and possibly,
by extrapolation, only in especially vulnerable people).
Although these physiological effects are unrelated to
thereasonthatthe additivewasplacedinthefood, they
may have important health implications just the same,
giventhe verylarge numberofAmericanswho arerou-
tinely exposed to environmental constituents added toMAHER AND WURTMAN
thefood supply. Ifonly 1%ofthe 100,000,000Americans
thought to consume aspartame ever exceed the sweet-
ener's ADI, and if only 1% of this group happen coin-
cidentally to have an underlying disease that makes
their brains vulnerable to the effects of an aspartame-
inducedriseinbrainphenylalaninelevels, thenthenum-
ber of people who might manifest adverse brain reac-
tions attributable to aspartame would still be about
10,000, a number on the same order as the number of
neurally related consumer complaints already regis-
tered with the FDA and other federal agencies (5,6).
This report describes some ofthe available evidence,
almost all ofwhich has been accumulated in the past 2
years, that doses of aspartame which are within the
range actually consumed by some people can affect the
chemicalcomposition ofthebrain, andmaythereby con-
tribute to particular CNS side effects, including head-
aches (7), inappropriate behavior responses (8,9), and
seizures (10,11). As will be noted, progress in antici-
patingaspartame's effects on the human brain has been
hampered by aparticular experimental problem related
to differences in the speeds at which the rodent and
human livers metabolizephenylalanine, theloneneutral
amino acid in aspartame, to tyrosine. The major bio-
chemical effect of aspartame, in humans, is to raise
blood and, presumably, brain phenylalanine levels (12);
in contrast, its main effect in rodents is to raise blood
(and brain) tyrosine levels (13,14), and tyrosine is often
the antidote tophenylalanine's effects onthebrain. This
species difference (which makes questionable the ex-
trapolation ofmuch ofthe rodent llterature to humans)
then canbe circumvented byusingthe rats ormice only
as a source oftissues for in vitro studies, or by admin-
istering the aspartame in doses that transiently over-
whelm the animals' capacity to metabolize it so that, as
happens when people consume any dose, the sweetener
causes brainphenylalanine toriseproportionately more
than brain tyrosine.
The existence of this major metabolic difference be-
tween rodents and people underscores the necessity
that large-scale human studies be carried out, prefer-
ably on selected populations whose members might be
especially vulnerable to phenylalanine and to aspar-
tame's other breakdown products, before conclusions
be drawn about whether ornot aspartame reallyis risk-
free. Ifaspartame cannot be shown to be risk-free, per-
haps its regulatory classification could be changed; for
example, to that of over-the-counter drug. Or perhaps
the federal regulation ofnovel food additives should be
modified torequire that adverse reactionsbe monitored
and reported, and that continuing research on their
safety be carried out as mandated by the FDA.
Effects of Dietary Aspartame on
Brain Phenylalanine Levels:
Possible Consequences for
Neurotransmission
The consumption of an aspartame-laden food or bev-
erage contributes to the plasma the three natural com-
pounds contained within the aspartame molecule: the
amino acids phenylalanine and aspartic acid, and the
alcohol methanol (15), possibly as well as various pep-
tides (like ,-aspartame or the aspartyl-phenylalanine
diketopiperazine) that are formed from it sponta-
neously, on the shelf, or enzymatically, after its con-
sumption. Ourpresent concern isaboutthe CNSeffects
of the phenylalanine. The aspartic acid is unlikely to
cross the blood-brain barrier (4), and very few data are
available showingthat the amounts ofmethanol orpep-
tides generated by ADI doses of aspartame have sig-
nificant neural effects. Underlying our concern about
the possible brain effects of the phenylalanine in ADI
aspartame doses (approximately 2 g in a 175 lb man)
are the following relationships:
Plasma phenylalanine levels are notregulated by any
known homeostatic mechanism. At any particular time
plasma levels simply reflect the amounts of phenylala-
nine being absorbed fromthe foods most recently eaten
(16,17). Thus, phenylalanine levels can normally vary
between 30 and 90 ,uM, depending upon whether the
subject has most recently eaten no-protein (i.e., phen-
ylalanine-free) or high-protein meals. Consumption of
the ADI aspartame dose is thus able to elevate plasma
phenylalanine levels about threefold (18).
Consumption of dietary phenylalanine in the usual
way, as a constituent ofprotein, does not elevate brain
phenylalanine levels (19). This is because the protein
elevates plasma levels ofthe other large neutral amino
acids (LNAA) (valine, leucine, isoleucine, tryptophan,
tyrosine) morethanthose ofphenylalanine. These other
amino acids are considerably more abundantthanphen-
ylalanine in the protein, and the branched-chain amino
acids, unlike phenylalanine, are largely unmetabolized
when they pass through the portal circulation (20).
In contrast, consumption ofphenylalanine intheform
of aspartame, with the other LNAA, that are always
present in proteins, elevates plasma phenylalanine lev-
els without elevating those of the other LNAA, this
causes marked elevations in the plasma phenylalanine
ratio (the ratio of the plasma phenylalanine concentra-
tion to the summed concentrations ofthe other LNAA)
(13). It should be noted that aspartame is probably the
only phenylalanine-containing food that man has ever
eaten which elevates this ratio.
An elevationinthe plasmaphenylalanineratio causes
a parallel rise in brain phenylalanine levels, since a sin-
gletransportmacromolecule withintheendothelialcells
lining the brain's capillaries mediates the uptake of all
ofthe LNAA; thismacromolecule isunsaturated atnor-
malplasma LNAAlevels; and each ofthe LNAA's com-
pete for attachment to it, their success depending on
their relative affinities for it and their plasma concen-
tration relative to those of its competitor (4,21). The
elevation in the plasma phenylalanine ratio also tends
toreducethe correspondingratiosforthe otherLNAA,
thusdecreasingtheirbrainuptakesandtendingtolower
their brain levels (13). [Aspartame fails to lower brain
tyrosine levels in the rat because the rat's liver hy-
droxylates dietaryphenylalanine sorapidlythatplasma
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tyrosine levels rise even more than those of plasma
phenylalanine (13,14). However, in humans dietary as-
partame probably reduces brain tyrosine uptake, de-
pending on the dose consumed.]
If an aspartame-containing beverage is consumed
along with, for example, a carbohydrate-rich, protein-
poordessert food, its effects on brain phenylalanine are
doubled (13). This is because the insulin secretion elic-
ited by the carbohydrate selectively lowers plasma lev-
els of the branched-chain amino acids (by facilitating
theiruptake into skeletalmuscle), without havingmuch
ofan effect on plasma phenylalanine; this increases the
effect of the aspartame on the plasma phenylalanine
ratio (17). A similar doubling may occur if the eater
happens to be one ofthe perhaps 10 million Americans
(22) who are, without knowing it, heterozygous for the
phenylketonuria (PKU) gene.
Once within brain, neurons producing certain neu-
rotransmitters, suchasdopaminergicnigrostriatalcells,
the excess phenylalanine can inhibit enzymes (like ty-
rosine hydroxylase) needed to synthesize the neuro-
transmitters. Excess circulating phenylalanine can also
diminishtheproductionofbraincatecholamines and ser-
otonin by competing with their precursor amino acids
for transport across the blood-brain barrier. Hence,
physiological processes that depend on the sustained
release ofadequate quantities ofthese transmitters can
be affected.
One such process, in rodents, is the suppression of
seizure activity. It has been recognized for years that
animals given drugs [such as reserpine or Ro 4-1284
(23)] that deplete the brain of particular monoamine
neurotransmitters, orthat block the receptor-mediated
effects ofthese transmitters, exhibit greatersensitivity
to seizures (23). In contrast, drugs [suchas L-Dopaplus
an MAO inhibitor, or L-Dops (23)] thought to enhance
monoaminergic neurotransmission apparently protect
rodents againstthe development ofseizures. Low doses
of aspartame, which raise plasma tyrosine levels more
than those ofphenylalanine, might be expected to have
no effect on seizure thresholds, or even to protect an-
imals against the epileptogenic effects ofdrugslikepen-
tylenetetrazole; in contrast, comparable doses, given to
humans, could enhance seizure susceptibility, since, in
humans, all aspartame doses apparently cause greater
increases in plasma (and brain) phenylalanine than in
tyrosine. (As shown below, sufficiently high aspartame
doses, which transiently exceed the liver's capacity to
hydroxylate phenylalanine, can also potentiate seizures
in rodents, whether these seizures are generated by
drugs, electroshock, or inhalation offluorothyl.)
All of these relationships have now been demon-
strated; most recently, the ability of phenylalanine to
suppressdopamine releasefromtherat'sbrainhasbeen
demonstrated. Slices of caudate nucleus were super-
fused with a solution containing sufficient tyrosine (50
,uM) to sustaindopamine'srelease, and were stimulated
electrically [360 pulses; 12 Hz; 2 msec (24)] on two oc-
casions, separated by an interval ofabout 60 min. The
addition ofphenylalanine to the medium caused a dose-
related suppresion of subsequent dopamine release
(shown as a reduction in the S2/S1 ratio). The lowest
phenylalanine concentration capable of impairing do-
pamine release (200 ,uM) was about three times that
presentinplasmasfromfastingrats. Anaspartamedose
that causes a proportionate threefold rise in the human
phenylalanine content ofplasmaistheADI dose (50mg/
kg). As explained above, this dose probably falls to 25
mg/kgiftheaspartameisconsumedalongwithadietary
carbohydrate (13), or to 12.5 mg/kg if the person con-
suming it in this manner also happens to be heterozy-
gous for PKU.
Effects of Aspartame on Seizure
Susceptibility in the Mouse
Todetermine whetheraspartame intakecouldmodify
seizuresusceptibility, perhapsbyincreasingplasmaand
brain phenylalanine levels, one of our group has ex-
amined its effects on the incidence of seizures, their
speed of onset, and the amount of convulsant required
to produce the seizures among mice given treatments
known to be epileptogenic (25). In general, animals re-
ceived various aspartame doses 1 hr before aCD50dose
ofthe seizure-inducing treatment, or a fixed aspartame
dose 1 hr before various doses of the treatment. The
number of animals in each treatment group exhibiting
seizures in the next 60 min were counted (when the
treatment was pentylenetetrazole), or the time passing
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FIGURE 1. Effect of aspartame pretreatment on the percentage of
mice convulsing following the administration ofthe CD50 dose of
pentylenetetrazole. Groups ofmale CD-1 mice (average n = 24)
received 0-2000 mg/kg aspartame via oral intubation followed by
an SC injection of pentylenetetrazole 1 hr later. The number of
mice convulsing with the various aspartame doses was deter-
mined.p < 0.05, significantlydifferentfrom0mg/kgasdetermined
by the chi-square test.
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FIGURE 2. Effect of aspartame (1000 mg/kg) on the percentage of
mice convulsing at various doses of pentylenetetrazole. Groups
(average n = 24) or male CD-1 mice received water or 1000
mg/kg aspartame via oral intubation followed by various doses of
pentylenetetrazole, 1 hr later. The number ofanimals convulsing
was determined. Aspartame pretreatment significantly
(p < 0.05) shifted the dose-response curve as determined by the
method of Litchfield and Wilcoxon.
until a given animal had a seizure (when the treatment
was inhaled fluorothyl or electroshock). The aspartame
dosesusedwerethoseshown, inthemice, tocauseblood
phenylalanine levels to rise by at least as much as blood
tyrosine, i.e., doses of 1000 mg/kg or greater.
Aspartame administration produced a dose-depen-
dent increase in seizure frequency among animals sub-
sequently receivingthe CD50dose ofpentylenetetrazole
(PTZ) (65 mg/kg) (Fig. 1). At the 1000 and 2000 mg/kg
aspartame doses, 78 and 100% of the animals experi-
enced seizures, compared with 50% in the water-pre-
treated group (26). Other mice pretreated with a fixed
dose (1000 mg/kg) of aspartame, or with water, and
given various doses (50-75 mg/kg) ofPTZ an hour later
exhibited a significant leftward shift of the PTZ dose-
response curve (Fig. 2). Enhanced susceptibility to
PTZ-induced seizures was also observed among mice
pretreated with phenylalanine (in doses equimolar to
effective aspartame doses), but not among animals pre-
treated with aspartic acid or methanol. Coadministra-
tion with aspartame of the LNAA valine, which com-
petes with phenylalanine for passage across the blood-
brain barrier (4,21), protected mice from the seizure-
promotingeffects ofthe sweetener; incontrast, alanine,
an amino acid which does not compete with phenylala-
nine for brain uptake, failed to attenuate aspartame's
effect on PTZ-induced seizures.
A seizure-promoting effect ofaspartame was also ob-
served in mice developing seizures in response to fluo-
rothyl or to electroshock. Animals were pretreated 60
min before exposure to 10% fluorothyl (delivered in a
sealed chamber at a rate of0.05 mL/min), and the time
each took to develop clonus was measured. Water-pre-
treated control animals experienced clonus at 462 + 18
see, while those receiving aspartame (1000 mg/kg) ex-
perienced clonus 35% sooner (298 + 10 see) (p < 0.001)
(26). Thisenhancementofseizuresusceptibilitywasalso
mimicked by equimolar phenylalanine (but not aspartic
acid) and blocked by valine, which, given alone, failed
to alter the time to clonus. Aspartame (1000 mg/kg ad-
ministered for 7 consecutive days) also accelerated the
onsetofhindlimbflexionamongmicegivenelectroshock
(50 mA, 60 Hz, 0.2 see), a response that was mimicked
by equimolar phenylalanine (Pinto and Maher, unpub-
lished observations).
Discussion
The above data indicate that APM has seizure-pro-
moting activity in animal models that are widely used
to identify compounds affecting (i.e., usually protecting
against) seizure incidence. That its mechanism ofaction
involves increased brain phenylalanine is indicated by
the ability of equimolar phenylalanine to simulate the
epileptogenic effect and by the ability of concurrently
administered valine to protect against this effect. The
evidence does not indicate that aspartame itself causes
seizures; ratheritpromotes seizures in animals that are
already at risk (that is, animals treated with PTZ, fluo-
rothyl, or electroshock). In a similar manner, it is pos-
sible that doses ofthe sweetener that cause a sufficient
increase in brain phenylalanine might increase seizure
frequency among susceptible humans, or might allow
seizures to occurin people who are vulnerable but with-
out prior episodes. Whether or not aspartame actually
does promote seizures in susceptible humans will have
to be explored in controlled clinical trials.
Itisunfortunate butperhapsnotsurprisingthatques-
tions about aspartame's phenylalanine-mediated neu-
rologic effects arose after the sweetener was added to
the food supply. New clinical data and the development
of new hypotheses, based on laboratory research, can
raise questions about any relatively new compound,
even after that compound has passed all of the safety
tests required at the time of its approval. What seems
most important is that processes be developed for mon-
itoring possible adverse reactions after food additives
are placed in the food supply, and for continuing the
conduct ofgovernment-mandated safety research. Per-
haps experience with aspartame will cataylze the de-
velopment of such processes.
These studies were supported in part by a grant from the National
Institute of Neurological, Communicative Diseases and Stroke
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